葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GSK 葛兰素史克

未开盘 03-27 16:00:00 EDT

53.84

-0.10

-0.19%

盘后53.72

-0.12-0.22%

18:55 EDT

最高54.75	最低53.79	成交量303.42万
今开54.23	昨收53.94	日振幅1.78%
总市值1,093亿	流通市值1,048亿	总股本20.31亿
成交额1.65亿	换手率0.16%	流通股本19.47亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"GSK","market":"US","secType":"STK","nameCN":"葛兰素史克","latestPrice":53.84,"timestamp":1774641600000,"preClose":53.94,"halted":0,"volume":3034219,"hourTrading":{"tag":"盘后","latestPrice":53.72,"preClose":53.84,"latestTime":"18:55 EDT","volume":16226,"amount":873583.8844,"timestamp":1774652137305,"change":-0.12,"changeRate":-0.002229,"amplitude":0.002415},"delay":0,"changeRate":-0.0018539117538004138,"floatShares":1946891708,"shares":2030886800,"eps":3.736205,"marketStatus":"未开盘","change":-0.1,"latestTime":"03-27 16:00:00 EDT","open":54.225,"high":54.75,"low":53.79,"amount":164532142.513727,"amplitude":0.017798,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":3.736205,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":0,"adr":1,"adrRate":2,"listingDate":977893200000,"exchange":"NYSE","adjPreClose":53.94,"dividendRate":0.032738,"preHourTrading":{"tag":"盘前","latestPrice":54.24,"preClose":53.94,"latestTime":"09:28 EDT","volume":13517,"amount":733120.98832,"timestamp":1774618083783,"change":0.3,"changeRate":0.005562,"amplitude":0.011123},"postHourTrading":{"tag":"盘后","latestPrice":53.72,"preClose":53.84,"latestTime":"18:55 EDT","volume":16226,"amount":873583.8844,"timestamp":1774652137305,"change":-0.12,"changeRate":-0.002229,"amplitude":0.002415},"volumeRatio":0.5921343681663146,"impliedVol":0.3223,"impliedVolPercentile":0.76},"requestUrl":"/m/hq/s/GSK","defaultTab":"news","newsList":[{"id":"2622850002","title":"曾长期缺货，葛兰素史克乙肝疫苗安在时重返中国市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2622850002","media":"红星资本局","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622850002?lang=zh_cn&edition=full","pubTime":"2026-03-26 20:36","pubTimestamp":1774528560,"startTime":"0","endTime":"0","summary":"红星资本局3月26日消息，一款在2022年就被传出缺货的进口乙肝疫苗，宣布重返中国市场。3月25日，葛兰素史克（GSK）宣布与科园信海（北京）医疗用品贸易有限公司（简称“上药科园贸易”）就乙肝疫苗安在时（EngerixB，重组乙型肝炎疫苗（酿酒酵母））启动战略合作。GSK表示，2026年正值安在时全球上市40周年，此次重返中国市场是满足市场需求的有力举措。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603263685856696.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4532","BK4614","ASHR","BK4588","DRAG","GSK.UK","BK4504","CQQQ","LU1829250122.USD","GSK","BK4007","KWEB","GSKH","BK4585","ASHS","LU0963586101.USD"],"gpt_icon":1},{"id":"2622029595","title":"GSK与上药科园贸易就乙肝疫苗安在时启动战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2622029595","media":"南方财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622029595?lang=zh_cn&edition=full","pubTime":"2026-03-25 16:48","pubTimestamp":1774428480,"startTime":"0","endTime":"0","summary":"南方财经3月24日电，记者获悉，今日，葛兰素史克（GSK）与上药科园贸易宣布双方将基于既有疫苗业务合作的良好基础之上，就GSK旗下乙肝疫苗安在时?（EngerixB，通用名：重组乙型肝炎疫苗(酿酒酵母)）开展深层次的协同与商业模式创新。本次合作模式不仅是单一的进口与分销安排，更是一个以市场协同和规模化覆盖为核心的战略型商业合作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603253684092524.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","BK4532","GSKH","BK4585","LU1829250122.USD","BK4007","GSK.UK","GSK"],"gpt_icon":0},{"id":"2621777224","title":"葛兰素史克向中国发展高层论坛2026年年会提交专题报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2621777224","media":"中国经济网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621777224?lang=zh_cn&edition=full","pubTime":"2026-03-23 14:38","pubTimestamp":1774247880,"startTime":"0","endTime":"0","summary":"3月22日至23日，中国发展高层论坛2026年年会在北京举行。葛兰素史克(GSK)向年会提交专题报告《健康优先战略下的价值转型：以乙肝功能性治愈为突破口，从“被动治疗”迈向“主动健康”》。当 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260323/c675476004.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260323/c675476004.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK4588","GSKH","BK4532","LU1829250122.USD","GSK","GSK.UK","BK4585","BK4007"],"gpt_icon":0},{"id":"2621724755","title":"跨国药企集体“加仓”中国：一场超千亿元的信任投票","url":"https://stock-news.laohu8.com/highlight/detail?id=2621724755","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621724755?lang=zh_cn&edition=full","pubTime":"2026-03-23 13:13","pubTimestamp":1774242780,"startTime":"0","endTime":"0","summary":"在阿斯利康宣布计划于2030年前在中国投资逾1000亿元人民币（150亿美元），以扩大在药品生产与研发领域的布局后，多家跨国药企（MNC）接连宣布加大中国市场投资。近日，中国发展高层论坛2026年年会现场涌动着一股“MNC投资热度”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603233680398150.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603233680398150.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","GSK.UK","GSK","GSKH","BK4007","BK4585","BK4532","LU1829250122.USD"],"gpt_icon":0},{"id":"2621520765","title":"蛇串疮百亿级市场的“冰与火”：GSK全球市场“独舞” 百克生物遭遇“极寒”","url":"https://stock-news.laohu8.com/highlight/detail?id=2621520765","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621520765?lang=zh_cn&edition=full","pubTime":"2026-03-21 10:20","pubTimestamp":1774059600,"startTime":"0","endTime":"0","summary":"春寒料峭谨防“会呼吸的痛”。随着春季气温波动，病毒进入活跃期，流行病传染病高发。带状疱疹，这个民间俗称“蛇串疮”的疾病，正以极高发病率威胁着大众健康。2025年发布的《中国带状疱疹疾病负担与经济学评价研究》显示，带状疱疹新发病例呈现年轻化，全人群终身发病风险超过30%。而与庞大市场需求形成鲜明对比的是，国内疫苗接种率的持续低迷。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603213679560322.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603213679560322.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","LU1829250122.USD","GSK.UK","BK4585","GSK","BK4532","688276","BK4007","BK0239","GSKH"],"gpt_icon":0},{"id":"2620950692","title":"股海导航_2026年3月19日_沪深股市公告与交易提示","url":"https://stock-news.laohu8.com/highlight/detail?id=2620950692","media":"股市直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620950692?lang=zh_cn&edition=full","pubTime":"2026-03-19 07:16","pubTimestamp":1773875760,"startTime":"0","endTime":"0","summary":"　　基蛋生物公告称，公司股票于3月16日、17日、18日连续3个交易日收盘价格涨幅偏离值累计达20%，构成交易异常波动。公司目前拟筹划出售控股子公司上海绿馨电子科技有限公司60%的股权，相关交易可能对公司净利润造成小幅度影响，可能触发信息披露标准。　　众泰汽车公告称，公司全资子公司浙江深康汽车车身模具有限公司于3月18日复工复产，正式恢复生产经营。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2026-03-19/doc-inhrnkuc8857594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["GSK.UK","BK4532","LU1829250122.USD","BK4588","GSKH","BK4007","GSK","BK4585"],"gpt_icon":0},{"id":"2620235848","title":"4000万美元首付款到账：前沿生物与GSK授权合作协议持续推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2620235848","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620235848?lang=zh_cn&edition=full","pubTime":"2026-03-18 16:15","pubTimestamp":1773821756,"startTime":"0","endTime":"0","summary":"3月18日，前沿生物（688221）发布公告，截至本公告披露日，公司已收到由葛兰素史克（GSK.N）按协议约定支付的4000万美元首付款。据悉，2026年2月16日，公司与葛兰素史克签署独家授权许可协议，葛兰素史克将获得两款小核酸（siRNA）管线产品在全球范围内的独家开发、生产及商业化权利。2025年前三季度，前沿生物实现收入1.03亿元，归母净利润-1.60亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603183675959935.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","BK0239","GSKH","GSK.UK","BK4588","688221","BK4532","GSK","BK4007","LU1829250122.USD"],"gpt_icon":0},{"id":"2620942079","title":"GSK(GSK.US)乙肝新药在中国拟纳入优先审评 有望实现乙肝功能性治愈","url":"https://stock-news.laohu8.com/highlight/detail?id=2620942079","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620942079?lang=zh_cn&edition=full","pubTime":"2026-03-17 21:33","pubTimestamp":1773754400,"startTime":"0","endTime":"0","summary":"此前该药已在国内获得突破性疗法资格，此次拟纳入优先审评，意味着这款全球首个有望实现乙肝功能性治愈的反义寡核苷酸类疗法距离中国患者又近一步。若获批，Bepirovirsen将成为全球首个仅需6个月有限疗程治疗便可实现乙肝功能性治愈的抗病毒疗法。GSK计划于2026年第一季度正式启动全球监管审批申请，该药已在日本申报上市。Bepirovirsen显示出具有统计学与临床意义的功能性治愈率。与单用标准治疗相比，bepirovirsen联合标准治疗显著提高了功能性治愈率。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","GSK.UK","LU1829250122.USD","GSK","BK4532","BK4007","BK4585","GSKH"],"gpt_icon":0},{"id":"2619619172","title":"葛兰素史克RSV疫苗获美国FDA批准扩大适用人群","url":"https://stock-news.laohu8.com/highlight/detail?id=2619619172","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619619172?lang=zh_cn&edition=full","pubTime":"2026-03-13 19:43","pubTimestamp":1773402180,"startTime":"0","endTime":"0","summary":"英国制药企业葛兰素史克周五宣布，美国食品药品监督管理局已扩大其呼吸道合胞病毒疫苗 Arexvy 的获批适用年龄范围，新增纳入18 至 49 岁因该病毒引发下呼吸道疾病风险升高的成年人群。该疫苗此前已在美国获批，用于60 岁及以上成年人，以及50 至 59 岁高危成年人群，预防 RSV 相关疾病。葛兰素史克表示，据估算，美国有2100 万50 岁以下成年人至少存在一项重症 RSV 感染的风险因素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-13/doc-inhqvxri7799401.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LABU","BK4007","GSK","159646","GSK.UK","BK4532","BK4585","BK4588","LU1829250122.USD","GSKH"],"gpt_icon":0},{"id":"2618933958","title":"跨国药企2025年成绩单：“药王”易主，创新资产交易创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2618933958","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618933958?lang=zh_cn&edition=full","pubTime":"2026-03-10 17:04","pubTimestamp":1773133472,"startTime":"0","endTime":"0","summary":"随着跨国药企陆续披露2025年业绩报告，全球制药行业的新一轮竞争格局逐步清晰。业绩榜单中，强生以全球941.93亿美元的总营收斩获榜首，旗下创新制药和医疗科技两大核心业务板块分别收入604.01亿美元（+6%）和337.92亿美元（+6.1%）；礼来凭借44%的高增速，实现651.79亿美元的全年营收，成为增速最快的头部药企。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603103667509930.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603103667509930.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1983299246.USD","IE00BJJMRZ35.SGD","NVOH","SG9999015358.SGD","IE00BLSP4452.SGD","SG9999001176.USD","IE00B1BXHZ80.USD","LU2361045086.USD","IE00BN8TJ469.HKD","LU2324357040.USD","BK4559","GSKH","LU1989772840.SGD","LU2360032135.SGD","LU0098860793.USD","LU0266013472.USD","LU1571399168.USD","LU0868494617.USD","SGXZ57979304.SGD","BK4588","IE00BKVL7J92.USD","LU1066051225.USD","LU1057294990.SGD","MRK","LU2361044865.SGD","BK4550","01477","LU0648001328.SGD","LU0289739699.SGD","NVOX","LU0130517989.USD","LU1093756325.SGD","LU1934455863.HKD","BK4534","LU1291159041.SGD","LU1023059063.AUD","BK4516","SG9999014575.USD","SG9999014542.SGD","GSK.UK","CDE","LU0203347892.USD","GSK","NVO","LU2125154778.USD","LU0320765489.SGD","LU1066051811.HKD","BK4585","LU1223082519.USD","LU0477156953.USD"],"gpt_icon":1},{"id":"2614701423","title":"葛兰素史克(GSK.US)9.5亿美元收购35 Pharma，发力心血管药物赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2614701423","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614701423?lang=zh_cn&edition=full","pubTime":"2026-02-25 16:45","pubTimestamp":1772009150,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，葛兰素史克已同意收购 35Pharma Inc.，这是一家拥有早期高血压药物资产的生物技术公司。此举标志着这家英国制药巨头正向心血管药物领域扩张。葛兰素史克在周三的一份声明中表示，将以 9.5 亿美元现金收购这家私人持有的加拿大公司。葛兰素史克目前最大的财务压力来自于其支柱性 HIV 药物将在 2028 年前后遭遇专利到期。1月20日，葛兰素史克还宣布收购美国上市药企RAPT Therapeutics。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407116.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"葛兰素史克(GSK.US)9.5亿美元收购35 Pharma，发力心血管药物赛道","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4532","BK4588","GSK.UK","GSK","LU1829250122.USD","GSKH","BK4007","BK4585"],"gpt_icon":0},{"id":"2613764331","title":"超10亿美元！前沿生物牵手GSK 小核酸赛道再升温","url":"https://stock-news.laohu8.com/highlight/detail?id=2613764331","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613764331?lang=zh_cn&edition=full","pubTime":"2026-02-24 14:08","pubTimestamp":1771913295,"startTime":"0","endTime":"0","summary":"小核酸领域再迎重磅BD（商务拓展）交易。2月23日晚间，科创板创新药企前沿生物（688221.SH）公告，已与葛兰素史克（GSK）达成一项独家授权许可协议，GSK获得公司两款小核酸（siRNA）管线产品在全球范围内的独家开发、生产及商业化权利。协议显示，其中一款候选药物已进入新药临床试验申请（IND）阶段，另一款为临床前候选药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602243652625697.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602243652625697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSKH","LU1829250122.USD","GSK.UK","BK4588","BK4532","BK4585","GSK","BK4007","688221","BK0239"],"gpt_icon":0},{"id":"2613788810","title":"前沿生物(688221.SH)与葛兰素史克签署授权许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2613788810","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613788810?lang=zh_cn&edition=full","pubTime":"2026-02-23 16:57","pubTimestamp":1771837051,"startTime":"0","endTime":"0","summary":"智通财经APP讯，前沿生物 发布公告，公司与全球生物制药企业葛兰素史克达成一项独家授权许可协议。葛兰素史克将负责两款产品之后所有的全球临床开发、监管申报及商业化活动。本次与全球领先的生物制药企业GSK达成此项协议，体现了公司在小核酸药物研发领域的技术实力与平台价值正获得国际市场认可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406324.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GSK.UK","GSKH","LU1829250122.USD","BK4588","GSK","BK4532","688221","BK4585","BK0239","BK4007"],"gpt_icon":0},{"id":"2610642029","title":"国家药监局受理葛兰素史克重组呼吸道合胞病毒疫苗60岁及以上成人适应症的上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2610642029","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610642029?lang=zh_cn&edition=full","pubTime":"2026-02-10 20:12","pubTimestamp":1770725567,"startTime":"0","endTime":"0","summary":"南方财经2月10日电，葛兰素史克（LSE/NYSE:GSK）宣布，中国国家药品监督管理局（NMPA）药品审评中心（CDE）已受理其重组呼吸道合胞病毒疫苗（CHO细胞，AS01E佐剂系统）的上市申请，该疫苗用于60岁及以上的成人预防由RSV引起的下呼吸道疾病（LRTD）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602103646856626.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159646","BK4532","BK4007","GSK.UK","LU1829250122.USD","BK4588","BK4585","GSK"],"gpt_icon":0},{"id":"2610895456","title":"花旗：将葛兰素史克目标价提高至2250便士","url":"https://stock-news.laohu8.com/highlight/detail?id=2610895456","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610895456?lang=zh_cn&edition=full","pubTime":"2026-02-09 14:27","pubTimestamp":1770618421,"startTime":"0","endTime":"0","summary":"花旗集团将葛兰素史克目标股价从1900便士提高至2250便士。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260209/32007202.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["GSK"],"gpt_icon":0},{"id":"2609154718","title":"葛兰素史克2025财年实现净利润75.33亿美元，同比增加128.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609154718","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609154718?lang=zh_cn&edition=full","pubTime":"2026-02-07 00:01","pubTimestamp":1770393679,"startTime":"0","endTime":"0","summary":"2月7日，葛兰素史克公布财报，公告显示公司2025财年净利润为75.33亿美元，同比增加128.97%；其中营业收入为430.52亿美元，同比增加7.38%，每股基本收益为3.72美元。从资产负债表来看，葛兰素史克总负债606.55亿美元，其中短期债务40.51亿美元，资产负债比为1.36，流动比率为0.82。机构评级：截至2026年2月7日，当前有3家机构对葛兰素史克目标价做出预测，其中目标均价为51.10美元，其中最低目标价为48.30美元，最高目标价为55.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207000126a6dc451b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207000126a6dc451b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GSK"],"gpt_icon":0},{"id":"2609596419","title":"葛兰素史克(GSK)：欧盟委员会批准Nucala用于未受控的慢性阻塞性肺病","url":"https://stock-news.laohu8.com/highlight/detail?id=2609596419","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609596419?lang=zh_cn&edition=full","pubTime":"2026-02-06 21:29","pubTimestamp":1770384564,"startTime":"0","endTime":"0","summary":"金吾财讯 | 葛兰素史克(GSK)宣布，欧盟委员会已批准其单克隆抗体维持治疗药物Nucala用于未受控的慢性阻塞性肺病。该批准基于MATINEE III期试验的积极数据，其中在广泛具有嗜酸性粒细胞表型的COPD患者中，mepolizumab与安慰剂加标准护理相比，显示出在中度/重度急性加重年化率上的临床意义和统计学显著降低。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/N2I5NmMxMDRhMjE5ZjZkNDA5NWY5Njk1NzgzMjA0MDcxNDc1OTcyMzk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/N2I5NmMxMDRhMjE5ZjZkNDA5NWY5Njk1NzgzMjA0MDcxNDc1OTcyMzk=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"296967","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK.UK","BK4007","LU1829250122.USD","BK4532","BK4588","BK4585","GSK"],"gpt_icon":0},{"id":"2609961275","title":"葛兰素史克慢阻肺药物Nucala获欧盟批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2609961275","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609961275?lang=zh_cn&edition=full","pubTime":"2026-02-06 21:26","pubTimestamp":1770384368,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["FSXEmain","GSK","BK4588","BK4532","FESXmain","BK4007","GSK.UK","BK4585","LU1829250122.USD"],"gpt_icon":0},{"id":"2609530156","title":"广誉远聘任75后王鹏浩为副总裁，履历涵盖哈药股份、葛兰素史克","url":"https://stock-news.laohu8.com/highlight/detail?id=2609530156","media":"瑞财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609530156?lang=zh_cn&edition=full","pubTime":"2026-02-06 09:48","pubTimestamp":1770342509,"startTime":"0","endTime":"0","summary":"瑞财经 刘治颖2月2日，广誉远公告，董事会同意聘任王鹏浩为公司副总裁，任期自本次董事会决议生效之日起至选举产生新一届董事会之日止。王鹏浩，出生于1975年5月，工商企业管理学士。广誉远成立于1996-11-25，法定代表人为李晓军，注册资本为4.89亿元，主要从事中药产品的生产与销售。该公司大股东为神农科技集团有限公司，持股15.17%。2025年前三季度，广誉远营业收入为10.61亿元，同比上升18.71%；归母净利润为7888.4万元，同比上升11.16%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206094833a6d95257&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206094833a6d95257&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","BK4588","GSK","BK4007","LU1829250122.USD","GSK.UK","BK4585"],"gpt_icon":0},{"id":"2609530905","title":"GSK新帅上任，开启“精细化”研发与并购新阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2609530905","media":"MedTrend医趋势","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609530905?lang=zh_cn&edition=full","pubTime":"2026-02-05 17:05","pubTimestamp":1770282356,"startTime":"0","endTime":"0","summary":"GSK新任CEO Luke Miels在接替Emma Walmsley后，首次明确了他的管理风格：更激进的外部并购、更严苛的管线审查，以及向“以产品为中心”的转型。并购策略：寻找“隐藏在众目睽睽”的机会Miels 明确了GSK未来的交易逻辑，重点不再是单纯的大规模收购，而是精准的“补强型”收购，理想的交易范围在20亿-40亿美元之间。近日，GSK确认将在英国和美国裁减数百名研发人员，旨在精简组织架构。2026 年，处于转型期的GSK销售预计增长3%-5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205195933a4802856&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205195933a4802856&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4532","BK4585","LU1829250122.USD","BK4007","GSK.UK","GSK"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gsk.com","stockEarnings":[{"period":"1week","weight":0.0386},{"period":"1month","weight":-0.0957},{"period":"3month","weight":0.097},{"period":"6month","weight":0.3511},{"period":"1year","weight":0.3977},{"period":"ytd","weight":0.0979}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0852},{"period":"3month","weight":-0.0814},{"period":"6month","weight":-0.0419},{"period":"1year","weight":0.1182},{"period":"ytd","weight":-0.0701}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"GSK Plc于1999年12月6日在英国成立的公众服务有限公司，是一个世界领先的研究型制药和保健公司，由Glaxo Wellcome plc和SmithKline Beecham plc合并而成。公司致力于开发较现有治疗方案明显改善的新产品，为病人和政府、保险公司或其他第三方提供帮助。","yearOnYearQuotes":[{"month":1,"riseRate":0.586957,"avgChangeRate":0.013809},{"month":2,"riseRate":0.478261,"avgChangeRate":0.001243},{"month":3,"riseRate":0.608696,"avgChangeRate":0.018616},{"month":4,"riseRate":0.673913,"avgChangeRate":0.032633},{"month":5,"riseRate":0.413043,"avgChangeRate":-0.008096},{"month":6,"riseRate":0.586957,"avgChangeRate":0.009648},{"month":7,"riseRate":0.543478,"avgChangeRate":0.003945},{"month":8,"riseRate":0.586957,"avgChangeRate":0.005806},{"month":9,"riseRate":0.521739,"avgChangeRate":0.005973},{"month":10,"riseRate":0.521739,"avgChangeRate":0.013062},{"month":11,"riseRate":0.478261,"avgChangeRate":0.009917},{"month":12,"riseRate":0.608696,"avgChangeRate":0.014188}],"exchange":"NYSE","name":"葛兰素史克","nameEN":"GlaxoSmithKline PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供葛兰素史克(GSK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"葛兰素史克,GSK,葛兰素史克股票,葛兰素史克股票老虎,葛兰素史克股票老虎国际,葛兰素史克行情,葛兰素史克股票行情,葛兰素史克股价,葛兰素史克股市,葛兰素史克股票价格,葛兰素史克股票交易,葛兰素史克股票购买,葛兰素史克股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供葛兰素史克(GSK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}